Cargando…

Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study

Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Tingyan, Jiang, Rong, Pu, Hong, Yang, Huijuan, Tu, Dongsheng, Dai, Zhiyuan, Cai, Yunlang, Zhang, Yuqin, Cheng, Xi, Jia, Huixun, Tu, Ruiqin, Wang, Huaying, Tang, Jie, Luan, Yuting, Cai, Shumo, Zang, Rongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738091/
https://www.ncbi.nlm.nih.gov/pubmed/31383985
http://dx.doi.org/10.1038/s41416-019-0543-1
_version_ 1783450781730471936
author Shi, Tingyan
Jiang, Rong
Pu, Hong
Yang, Huijuan
Tu, Dongsheng
Dai, Zhiyuan
Cai, Yunlang
Zhang, Yuqin
Cheng, Xi
Jia, Huixun
Tu, Ruiqin
Wang, Huaying
Tang, Jie
Luan, Yuting
Cai, Shumo
Zang, Rongyu
author_facet Shi, Tingyan
Jiang, Rong
Pu, Hong
Yang, Huijuan
Tu, Dongsheng
Dai, Zhiyuan
Cai, Yunlang
Zhang, Yuqin
Cheng, Xi
Jia, Huixun
Tu, Ruiqin
Wang, Huaying
Tang, Jie
Luan, Yuting
Cai, Shumo
Zang, Rongyu
author_sort Shi, Tingyan
collection PubMed
description Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 218 patients with FIGO IIIC–IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49–1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47–0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer. Trial registration: ClinicalTrials.gov, NCT01669226 (date of registration: August 20, 2012).
format Online
Article
Text
id pubmed-6738091
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67380912020-08-06 Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study Shi, Tingyan Jiang, Rong Pu, Hong Yang, Huijuan Tu, Dongsheng Dai, Zhiyuan Cai, Yunlang Zhang, Yuqin Cheng, Xi Jia, Huixun Tu, Ruiqin Wang, Huaying Tang, Jie Luan, Yuting Cai, Shumo Zang, Rongyu Br J Cancer Brief Communication Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 218 patients with FIGO IIIC–IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49–1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47–0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer. Trial registration: ClinicalTrials.gov, NCT01669226 (date of registration: August 20, 2012). Nature Publishing Group UK 2019-08-06 2019-08-27 /pmc/articles/PMC6738091/ /pubmed/31383985 http://dx.doi.org/10.1038/s41416-019-0543-1 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Brief Communication
Shi, Tingyan
Jiang, Rong
Pu, Hong
Yang, Huijuan
Tu, Dongsheng
Dai, Zhiyuan
Cai, Yunlang
Zhang, Yuqin
Cheng, Xi
Jia, Huixun
Tu, Ruiqin
Wang, Huaying
Tang, Jie
Luan, Yuting
Cai, Shumo
Zang, Rongyu
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
title Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
title_full Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
title_fullStr Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
title_full_unstemmed Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
title_short Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
title_sort survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738091/
https://www.ncbi.nlm.nih.gov/pubmed/31383985
http://dx.doi.org/10.1038/s41416-019-0543-1
work_keys_str_mv AT shitingyan survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT jiangrong survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT puhong survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT yanghuijuan survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT tudongsheng survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT daizhiyuan survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT caiyunlang survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT zhangyuqin survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT chengxi survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT jiahuixun survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT turuiqin survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT wanghuaying survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT tangjie survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT luanyuting survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT caishumo survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT zangrongyu survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy
AT survivalbenefitsofdosedenseearlypostoperativeintraperitonealchemotherapyinfrontlinetherapyforadvancedovariancancerarandomisedcontrolledstudy